FDA rejects migraine treatment made by North Carolina company Satsuma Pharmaceuticals

A biopharmaceutical company headquartered in Research Triangle Park is facing a regulatory setback.

Source: bizjournals.com Health Care:Biotechnology headlines - January 22, 2024 Category: Biotechnology Authors: Zac Ezzone Source Type: news